Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ).
Pharmaron Beijing Co., Ltd. announced the resignation of Mr. Hu Baifeng from his position as a non-executive director and member of the strategy committee. Mr. Hu will continue his duties until a new director is elected at the 2024 AGM. The company has nominated Ms. Wan Xuan as a candidate for the non-executive director position, with her appointment subject to shareholder approval at the AGM. Ms. Wan, who has a background in investment management within the healthcare and biotechnology sectors, will also serve on the strategy committee if elected.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a joint stock company incorporated in China, operating within the healthcare and biotechnology industry. It focuses on providing a range of services and products related to pharmaceutical research and development.
YTD Price Performance: -10.53%
Average Trading Volume: 1,531
Technical Sentiment Signal: Buy
Current Market Cap: €4.52B
See more data about 3759 stock on TipRanks’ Stock Analysis page.